Celyad Oncology SA (NASDAQ:CYAD)

Delayed Data
As of Sep 26
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range

Stock Price Forecast

The 2 analysts offering 12-month price forecasts for Celyad Oncology SA have a median target of 5.40, with a high estimate of 8.00 and a low estimate of 2.80. The median estimate represents a +269.98% increase from the last price of 1.46.

Chart unavailable

Analyst Recommendations

The current consensus among 3 polled investment analysts is to Buy stock in Celyad Oncology SA. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past
months for detail


Earnings and Sales Forecasts

Current Quarter

Earnings per Share
Reporting Date
Aug 05

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly 9.40%
Growthannually 28.52%


Growthquarterly -100.00%
Growthannually --
Key to the earnings and sales forecast charts.